- GQ Magazine Pays Tribute to America's Top Research Scientists - - Also Featured Jeffrey Cummings, Chair of Prana's Biotechnology Research & Development Advisory Board - MELBOURNE, Australia, May 18 /PRNewswire/ -- Dr.

- Journal of Neuroscience paper describes role of Zinc in developing Alzheimer's - MELBOURNE, Australia, April 1 /PRNewswire-FirstCall/ -- Prana Biotechnology (ASX:PBT; Nasdaq: PRAN) today announced that an independent study conducted by researchers at the University of California, Irvine, validates Prana's fundamental drug strategy for Alzheimer's Disease in blocking the toxic interaction between Abeta and brain metals, such as zinc, that damages synapses and cause cognitive loss.

To: MEDICAL EDITORS Contact: Alzheimers Association media line, +1-312-335-4078, media@alz.org; ICAD 2008 press room, July 27-31, +1-312-949-3253 - Unsuccessful Phase III Study Does Not Mean the End of Anti- Amyloid Therapies - CHICAGO, July 29 /PRNewswire-USNewswire/ -- Results from four studies of potential new treatments for Alzheimer's - even an unsuccessful late stage clinical trial - increase the field's knowledge and point scientists toward advances in therapies for the disease, according to research reported today at the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD 2008), in Chicago.

Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, announced today the publication of the results of its Phase 2a clinical trial on Alzheimer's disease patients in The Lancet Neurology journal.

Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced that Dr.